Benjamin Ortiz to Anti-Asthmatic Agents
This is a "connection" page, showing publications Benjamin Ortiz has written about Anti-Asthmatic Agents.
Connection Strength
0.692
-
Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair N, Rowe PJ, Busse WW. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2023 04; 11(4):1213-1220.e2.
Score: 0.192
-
Rabe KF, FitzGerald JM, Bateman ED, Castro M, Pavord ID, Maspero JF, Busse WW, Izuhara K, Daizadeh N, Ortiz B, Pandit-Abid N, Rowe PJ, Deniz Y. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype. J Allergy Clin Immunol Pract. 2022 11; 10(11):2916-2924.e4.
Score: 0.188
-
Szefler SJ, Casale TB, Haselkorn T, Yoo B, Ortiz B, Kattan M, Busse WW. Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. J Allergy Clin Immunol Pract. 2020 09; 8(8):2673-2680.e3.
Score: 0.160
-
Li P, Kavati A, Puckett JT, Jahnke J, Busse P, Hanania NA, Ortiz B, Doshi JA. Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2020 02; 8(2):507-515.e10.
Score: 0.152